Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2371 to 2380 of 2579 total matches.

Resveratrol

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009  (Issue 1321)
in regulation of molecular mechanisms of aging. 1 Caloric restriction also increases sirtuin activity ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Med Lett Drugs Ther. 2009 Sep 21;51(1321):74-5 |  Show IntroductionHide Introduction

Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010  (Issue 1342)
of nonHodgkin’s lymphoma (NHL) in North America. 1 The most common subtypes are PTCL not otherwise specified ...
The FDA has approved pralatrexate (Folotyn – Allos), an intravenous (IV) antifolate, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the first drug approved by the FDA specifically for this indication.
Med Lett Drugs Ther. 2010 Jul 12;52(1342):55-6 |  Show IntroductionHide Introduction

A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013  (Issue 1412)
gradually over 5 years to 10 mcg/day.1 MECHANISM OF ACTION — Local progestogenic effects that interfere ...
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing contraceptive methods available in the US appears on page 22.
Med Lett Drugs Ther. 2013 Mar 18;55(1412):21-2 |  Show IntroductionHide Introduction

Comparison Chart: Correct Use of Inhalers for Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
, the inhaler is ready to use ▶ The dose indicator should count down by 1 ▶ Exhale fully ▶ Close lips around ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8   doi:10.58347/tml.2024.1716c |  Show IntroductionHide Introduction

Tinidazole (Tindamax) - A New Anti-Protozoal Drug

   
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004  (Issue 1190)
metronidazole 1.6 g divided into 2 doses to tinidazole 2 g once showed no differences in cure rates or adverse ...
Tinidazole (Tindamax - Presutti Labs), an oral antiprotozoal drug similar to metronidazole (Flagyl, and others), has been approved by the FDA for treatment of trichomoniasis in adults and for treatment of giardiasis, intestinal amebiasis and amebic liver abcess in adults and children more than 3 years old. Tinidazole has been widely used outside of the US for decades under the trade name Fasigyn (Pfizer).
Med Lett Drugs Ther. 2004 Aug 30;46(1190):70-2 |  Show IntroductionHide Introduction

Two New Drugs for Renal Cell Carcinoma

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007  (Issue 1255)
syndrome), but with a median duration of 54 months. 1 SUNITINIB — Mechanism of Action – Sunitinib ...
Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal stromal tumor (GIST) who are not responding to or are intolerant of standard therapy with imatinib (Gleevec).
Med Lett Drugs Ther. 2007 Feb 26;49(1255):18-20 |  Show IntroductionHide Introduction

Safety of SSRIs in Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008  (Issue 1299)
of selective serotonin reuptake inhibitors (SSRIs) in these women has been increasing. 1 Maternal depression ...
Depression occurs in up to 20% of pregnant women, and the use of selective serotonin reuptake inhibitors (SSRIs) in these women has been increasing. Maternal depression has itself been associated with intrauterine growth problems and low birth weight, so the risks of exposure to antidepressants during pregnancy must be weighed against the risks of untreated depression, which also include self-harm, poor bonding and poor parenting. SSRIs available in the US for treatment of depression include citalopram (Celexa, and others), escitalopram (Lexapro), fluoxetine (Prozac, and others), paroxetine...
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89-91 |  Show IntroductionHide Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023  (Issue 1691)
benefit may not be achieved for 4-8 weeks.1 FIRST-LINE DRUGS SSRIs — There is no convincing evidence ...
A selective serotonin reuptake inhibitor (SSRI) is generally used for initial treatment of major depressive disorder (MDD). A serotonin-norepinephrine reuptake inhibitor (SNRI), bupropion (Wellbutrin SR, and others), and mirtazapine (Remeron, and others) are reasonable alternatives. Improvement in symptoms can occur within the first two weeks of treatment with these drugs, but a substantial benefit may not be achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200   doi:10.58347/tml.2023.1691a |  Show IntroductionHide Introduction

Fluoxetine (Prozac) Revisited

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 1990  (Issue 826)
day) may be too high. Even the recommended initial dose of 20 mg (1 capsule) per day has caused ...
In the short time since fluoxetine (Prozac - Lilly) first became available in the USA (Medical Letter, 30:45, 1988), it has become the most frequently prescribed of all antidepressants. Some recent reports, however, have questioned its safety.
Med Lett Drugs Ther. 1990 Sep 7;32(826):83-4 |  Show IntroductionHide Introduction

High Altitude Sickness

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 1992  (Issue 878)
, Scientific American Medicine, New York:Sci Am, 1990-1992, page CTM:IX:1). Symptoms of exertional fatigue ...
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on prevention and treatment of these disorders has been reported.
Med Lett Drugs Ther. 1992 Sep 4;34(878):84-6 |  Show IntroductionHide Introduction